Paul Reider
Known title: Chief Commercial OfficerCIK: 0001970033
Associated companies
Transaction History
| CHRS | ▼ Sell | Tax Withholding | 4,858 | $7K | 1/20/2025 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 2,277 | $4K | 1/4/2025 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 2,073 | $3K | 12/13/2024 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 4,854 | $12K | 1/20/2024 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 2,275 | $7K | 1/4/2024 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 2,049 | $5K | 12/13/2023 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 2,451 | $17K | 4/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.